Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
Purpose of Review. This is a comprehensive review of the literature regarding the use of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the developmen...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Neurology International |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2035-8377/13/3/29 |
| _version_ | 1829091586347106304 |
|---|---|
| author | Kunal Maini Haley Gould Jessica Hicks Fatima Iqbal James Patterson Amber N. Edinoff Elyse M. Cornett Adam M. Kaye Omar Viswanath Ivan Urits Alan D. Kaye |
| author_facet | Kunal Maini Haley Gould Jessica Hicks Fatima Iqbal James Patterson Amber N. Edinoff Elyse M. Cornett Adam M. Kaye Omar Viswanath Ivan Urits Alan D. Kaye |
| author_sort | Kunal Maini |
| collection | DOAJ |
| description | Purpose of Review. This is a comprehensive review of the literature regarding the use of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the development of schizophrenia. Recent Findings. Schizophrenia is a chronic mental health disorder that currently affects approximately 3.3 million people in the United States. Its symptoms, which must be present for more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Aripiprazole lauroxil is a long-acting intramuscular injection that works as a combination of partial agonist activity at D<sub>2</sub> and 5-HT<sub>1A</sub> receptors combined with antagonist activity at 5-HT<sub>2A</sub> receptors. It can be dosed as a 4-, 6-, or 8-week injection, depending on oral dosage. Aripiprazole lauroxil was FDA approved in October of 2015. Summary. Schizophrenia is a severe psychiatric disorder if left untreated. There are multiple medications to help treat schizophrenia. One antipsychotic agent, aripiprazole lauroxil, offers long duration injections that optimize and improve compliance. Known side effects include weight gain, akathisia, neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension. Aripiprazole lauroxil is an FDA-approved drug that can be administered monthly, every six weeks, or every two months and has been shown to be both safe and effective. |
| first_indexed | 2024-03-10T07:21:35Z |
| format | Article |
| id | doaj.art-bdf947a570d74ff3a2e0bc43a1a0da52 |
| institution | Directory Open Access Journal |
| issn | 2035-8377 |
| language | English |
| last_indexed | 2024-03-10T07:21:35Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Neurology International |
| spelling | doaj.art-bdf947a570d74ff3a2e0bc43a1a0da522023-11-22T14:33:24ZengMDPI AGNeurology International2035-83772021-07-0113327929610.3390/neurolint13030029Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive ReviewKunal Maini0Haley Gould1Jessica Hicks2Fatima Iqbal3James Patterson4Amber N. Edinoff5Elyse M. Cornett6Adam M. Kaye7Omar Viswanath8Ivan Urits9Alan D. Kaye10Department of Psychiatry, Louisiana State University Shreveport, Shreveport, LA 71103, USAShreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USAShreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USAShreveport School of Medicine, Louisiana State University, Shreveport, LA 71103, USADepartment of Psychiatry, Louisiana State University Shreveport, Shreveport, LA 71103, USADepartment of Psychiatry, Louisiana State University Shreveport, Shreveport, LA 71103, USADepartment of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USADepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USACollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USADepartment of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USADepartment of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USAPurpose of Review. This is a comprehensive review of the literature regarding the use of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the development of schizophrenia. Recent Findings. Schizophrenia is a chronic mental health disorder that currently affects approximately 3.3 million people in the United States. Its symptoms, which must be present for more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Aripiprazole lauroxil is a long-acting intramuscular injection that works as a combination of partial agonist activity at D<sub>2</sub> and 5-HT<sub>1A</sub> receptors combined with antagonist activity at 5-HT<sub>2A</sub> receptors. It can be dosed as a 4-, 6-, or 8-week injection, depending on oral dosage. Aripiprazole lauroxil was FDA approved in October of 2015. Summary. Schizophrenia is a severe psychiatric disorder if left untreated. There are multiple medications to help treat schizophrenia. One antipsychotic agent, aripiprazole lauroxil, offers long duration injections that optimize and improve compliance. Known side effects include weight gain, akathisia, neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension. Aripiprazole lauroxil is an FDA-approved drug that can be administered monthly, every six weeks, or every two months and has been shown to be both safe and effective.https://www.mdpi.com/2035-8377/13/3/29schizophreniaschizophrenia treatmentaripiprazole lauroxillong-acting injectionsaristada |
| spellingShingle | Kunal Maini Haley Gould Jessica Hicks Fatima Iqbal James Patterson Amber N. Edinoff Elyse M. Cornett Adam M. Kaye Omar Viswanath Ivan Urits Alan D. Kaye Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review Neurology International schizophrenia schizophrenia treatment aripiprazole lauroxil long-acting injections aristada |
| title | Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review |
| title_full | Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review |
| title_fullStr | Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review |
| title_full_unstemmed | Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review |
| title_short | Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review |
| title_sort | aripiprazole lauroxil a novel injectable long acting antipsychotic treatment for adults with schizophrenia a comprehensive review |
| topic | schizophrenia schizophrenia treatment aripiprazole lauroxil long-acting injections aristada |
| url | https://www.mdpi.com/2035-8377/13/3/29 |
| work_keys_str_mv | AT kunalmaini aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT haleygould aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT jessicahicks aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT fatimaiqbal aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT jamespatterson aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT ambernedinoff aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT elysemcornett aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT adammkaye aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT omarviswanath aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT ivanurits aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview AT alandkaye aripiprazolelauroxilanovelinjectablelongactingantipsychotictreatmentforadultswithschizophreniaacomprehensivereview |